Alternative image
Press Release

March 18, 2026

Evonik launches new ceramide SPHINOX® Vively at PCHi 2026

Evonik announced the global launch of SPHINOX® Vively, an advanced designer sphingolipid engineered to elevate skin vitality through a unique synergy of biotechnology, barrier science, and high performance efficacy.

  • Breakthrough designer sphingolipid delivering visible skin rejuvenation
  • Retinol‑like efficacy with improved tolerance
  • Biotechnology‑powered and sustainability‑driven ingredient for modern skincare
  • Global debut at PCHi 2026 in Hangzhou, spotlighting China’s strong anti‑aging demand

Hangzhou, China. Evonik announced the global launch of SPHINOX® Vively, an advanced designer sphingolipid engineered to elevate skin vitality through a unique synergy of biotechnology, barrier science, and high‑performance efficacy. The ingredient makes its first global appearance at PCHi 2026 in Hangzhou, underlining China’s position as one of the world’s most dynamic markets for multidimensional anti‑aging innovation.

“Consumers today increasingly expect solutions that go beyond traditional anti‑aging. They look for ingredients that strengthen the skin holistically, perform visibly, and support long‑term skin vitality. SPHINOX® Vively was designed precisely to meet these expectations, combining cutting‑edge sphingolipid science with a more skin‑friendly alternative to conventional retinol,” said Silvana Estarita-Jäde, Head of Marketing Active Ingredients at Evonik’s Care Solutions business line.

As a new‑generation multifunctional bioactive sphingolipid, SPHINOX® Vively delivers retinol‑like rejuvenation with significantly improved tolerance. It stimulates elastin and hyaluronic acid production at a level comparable to unencapsulated retinol, yet without its typical irritation or barrier disruption. The ingredient also strengthens the skin barrier by increasing Ceramide AP and EOP levels, supporting faster recovery after external stress. By reducing IL‑1α release, SPHINOX® Vively helps maintain a calmer, more resilient skin environment, with visible improvements validated by robust scientific data.

Aligned with Evonik’s long‑standing commitment to responsible innovation, SPHINOX® Vively is biotechnology‑derived, readily biodegradable, and produced using partially renewable feedstocks— demonstrating how high efficacy and sustainability can coexist in one modern skincare ingredient.

As one of China’s most influential personal care ingredient exhibitions, PCHi 2026 takes place from March 18–20 in Hangzhou. A signature highlight of the event, the Fountain Awards celebrate innovations that advance the industry. Evonik has been honored multiple times for its pioneering contributions in ceramide and sphingolipid science, with previous award‑winning ingredients such as RHEASOME® CeraBoost and Bodyflux® Olive. These accolades underscore Evonik’s continued leadership and creativity in the field, now further reinforced by the global debut of SPHINOX® Vively.

Evonik Beauty & Personal Care is part of the company’s Care Solutions business line, dedicated to empowering brands to confidently create eco-friendly products that elevate consumer health and well-being. The business unites expertise across skin, hair, scalp, active ingredients, delivery systems, product protection, and more, working passionately to deliver tailored, sustainable solutions that bridge the gap between performance and responsibility.

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. The common motivation of the approximately 31,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.